OPEN

The Pharmacogenomics Journal (2017) 17, 403–411

www.nature.com/tpj

REVIEW

Systematic review and meta-analysis: pharmacogenetics of anti-TNF treatment response in rheumatoid arthritis

S Bek[1], AB Bojesen[1,2], JV Nielsen[1], J Sode[1], S Bank[1], U Vogel[2,3] and V Andersen[1,4,5,6]

Rheumatoid arthritis (RA) is a chronic inflammatory disease that affects ~ 1% of the Caucasian population. Over the last decades, the availability of biological drugs targeting the proinflammatory cytokine tumour necrosis factor α, anti-TNF drugs, has improved the treatment of patients with RA. However, one-third of the patients do not respond to the treatment. We wanted to evaluate the status of pharmacogenomics of anti-TNF treatment. We performed a PubMed literature search and all studies reporting original data on associations between genetic variants and anti-TNF treatment response in RA patients were included and results evaluated by meta-analysis. In total, 25 single nucleotide polymorphisms were found to be associated with anti-TNF treatment response in RA (19 from genome-wide association studies and 6 from the meta-analyses), and these map to genes involved in T cell function, NFκB and TNF signalling pathways (including *CTCN5, TEC, PTPRC, FCGR2A, NFKBIB, FCGR2A, IRAK3)*. Explorative prediction analyses found that biomarkers for clinical treatment selection are not yet available.

The Pharmacogenomics Journal (2017) **17,** 403–411; doi:10.1038/tpj.2017.26; published online 13 June 2017

INTRODUCTION

Rheumatoid arthritis (RA) is a chronic inflammatory disease that affects ~ 1% of the Caucasian population.[1] Disease onset typically manifests at age of 35–50 years, and females are affected 2.5 times more frequently than males. RA is characterised by synovial inflammation of joints most often affecting the joints of hands, wrist and feet, potentially leading to joint destruction, and functional disability. Furthermore, extra-articular manifestations may occur, for example, osteoporosis, vasculitis or interstitial lung disease. The manifestations are consequences of a chronically activated immune system. Both proinflammatory cytokines as tumour necrosis factor (TNF), interleukin (IL)-6, IL-8, GM-CSF, IL-1 and anti-inflammatory cytokines as IL-10 are involved. TNFα is a member of the TNF family of regulators of immune and inflammatory responses, which may also mediate cell death.[2]

In the 1980s, it was shown that TNFα has a prominent role in RA,[3–5] and over the past decades, the availability of drugs targeting tumour necrosis factor α (anti-TNF) has improved the treatment of RA patients. Nevertheless, only 60–70% of patients have a good to moderate response to the anti-TNF treatment, whereas 30–40% have no or insufficient response.[2,6] Apart from anti-TNF drugs, biological compounds targeting CD20, T-lymphocyte antigen 4 immunoglobulin, interleukin 6 receptor and B-cells have been developed.[7,8] Until now, the treatment paradigm has been 'one drug suits all'. Thereby, patients may remain in high disease activity, with irreversible joint damage as a possible consequence. Pharmacogenetics may identify the individual patient's signature that may help guide the treatment selection (reviewed in refs 9,10). Genetic variants may impact anti-TNF drug response.[9–16] They may therefore be utilised as biomarkers for treatment selection by stratifying patients according to the expected response following medical treatment. Furthermore, genetic biomarkers hold the advantage that they do not change over time.

Biomarkers able to predict treatment response will help optimising treatment, reduce adverse side-effects and avoid treatment with drugs without effect in the individual patients. In addition, such biomarkers will also help improving the use of health care resources. The expectations from patients, health care professionals and health authorities are high. 'Personalised medicine represents one of the most innovative new concepts in health care. It holds real promise for more effective early diagnosis and more effective and less toxic treatments for patients, for improved medical service to citizens, and for improving the overall health of the population' (http://permed2020.eu/., 2015). 'Personalised medicine refers to a medical model using characterisation of individual's phenotypes and genotypes (for example, molecular profiling, medical imaging, lifestyle data) for tailoring the right therapeutic strategy for the right person at the right time, and/or to determine the predisposition to disease and/or to deliver timely and targeted prevention' (http://permed2020.eu/., 2015). Until now, most advances in applied pharmacogenetics have taken place in the field of anticancer therapy.[17]

Thus, we undertook to review case–control studies on genetic variants associated with anti-TNF treatment response in RA patients.

MATERIALS AND METHODS

A systematic review and meta-analysis were carried out according to the guidelines of 'Preferred Reporting Items for Systematic

[1]Focused Research Unit for Molecular Diagnostic and Clinical Research, IRS-Center Sonderjylland, Laboratory Center, Hospital of Southern Jutland, Aabenraa, Denmark; [2]Research Unit for E-mental Health, Mental Health Services in the Region of Southern Odense, Odense, Denmark; [3]National Research Centre for the Working Environment, Copenhagen, Denmark; [4]Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark; [5]Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark and [6]Odense Patient Data Explorative Network, Odense University Hospital, Odense, Denmark. Correspondence: Professor V Andersen, Focused Research Unit for Molecular Diagnostic and Clinical Research, IRS-Center Sonderjylland, Laboratory Center, Hospital of Southern Jutland, Kresten Philipsens Vej 15, Aabenraa 6200, Denmark.
E-mail: Vibeke.Andersen1@rsyd.dk
Received 22 November 2016; revised 8 February 2017; accepted 2 March 2017; published online 13 June 2017



Figure 1. Flow diagram of included studies.

Reviews and Meta-Analyses' (PRISMA) statement.[18] Three individual searches were performed in PubMed combining various alternative search terms for (1) 'anti-TNF treatment', (2) 'genetic variation' and (3) 'autoimmune disease', respectively, resulting in 669 abstracts (latest search date: 29th of August 2016). A full list of search terms is found in Supplementary Table 1. Figure 1 shows the flow diagram of included studies. All studies suggesting that they presented original data on associations between polymorphisms and anti-TNF treatment response in autoimmune diseases were retrieved (170 articles) and reviewed by three independent authors (SiB, JVN, VA). Exclusion criteria were: <100 cases available for treatment evaluation, missing data on treatment response, not reporting original data and not reporting data on anti-TNF response in RA (122 studies). In total, 47 studies reported association between genetic markers and anti-TNF response in RA. No further studies were identified by searching the literature list of the retrieved articles. Data on study design, number of patients, response criteria, odds ratios (OR) and 95% confidence intervals (95% CI) or numbers of good responders, moderate and non-responders, and genotypes were included.

Statistics

Meta-analysis was performed on studies using EULAR response criteria.[19] All polymorphisms studied in at least two studies (with a minimum of one significant association with response), and where data on genotypes and treatment response could be retrieved, were included in a meta-analysis (30 studies). The meta-analysis was based on the total number of patients in the cohorts.

Table 1. Description of 43 candidate gene studies (candidate) and 5 GWAS on associations between polymorphisms and response to anti-TNF treatment in RA patients

Disease	*Ethnicity/country*	*Biological drug(s)*	*DMARDs*[a] *(%)*	*MTX*[a] *(%)*	*Response criteria bases on*	*Response evaluated after*	N *cases*	*Refs.*
Candidate								
RA	Caucasian, Spain	INX/ADM/ETC	100	57.7	ACR/EULAR		1239	Canet *et al.*[29]
RA	Caucasian, UK	INX/ADM/ETC	81.8	—	EULAR[b]/ΔDAS28[b]	3–6 months	1750	Smith *et al.*[23]
RA	Denmark	INX/ADM/ETC	84	73	EULAR[c]	3–6 months	1007	Sode *et al.*[15]
RA	Denmark	INX/ADM/ETC	83	72	EULAR[c]	3–6 months	469	Sode *et al.*[15]
RA	Caucasian, Poland	INX/ADM/ETC	—	93	EULAR[c]/ΔDAS28[d]	12 and 24 weeks	284	Iwaszko *et al.*[24]
RA	Denmark	INX/ADM/ETC	84	—	EULAR	2–6 months	538	Sode *et al.*[16]
RA	Caucasian, Poland	INX/ADM/ETC	—	92	EULAR[c]/ΔDAS28[d]	12 and 24 weeks	223	Iwaszko *et al.*[21]
RA	Spain and Greece	INX/ADM/ETC	95	—	EULAR[c]/ΔDAS28	3 and 6 months	755	Ferreiro-Iglesias *et al.*[28]
RA	Multicenter[e]	INX/ADM/ETC	—	86.2	EULAR[c]	6 months	471	Canet *et al.*[22]
RA	Portugal	INX/ADM/ETC	91.8	82.2	EULAR[f]/ΔDAS28	6 months	383	Canhão *et al.*[58]
RA	The Netherland	ADM	—	82.1	EULAR[g]/ΔDAS28	14 weeks	302	Dávila-Fajardo *et al.*[32]
RA	Spain and Greece	INX/ADM/ETC	94.6	—	EULAR/ΔDAS28	3, 6 and 12 months	423	Montes *et al.*[33]
RA	Poland	INX/ADM/ETC	—	92.5	EULAR[h]/ΔDAS28	6 months	280	Swierkot *et al.*[52]
RA	Denmark	INX/ADM/ETC	84.2	—	EULAR[c]/ACR50	3–6 months	538	Sode *et al.*[14]
RA	Spain and Greece	INX/ADM/ETC	88.4	—	EULAR[c]/ΔDAS28	3, 6 and 12 months	410	Montes *et al.*[56]
RA	Spanish	INX/ADM/ETC			EULAR/ΔDAS28	6 and 12 months	419	Márquez *et al.*[25]
RA	Spanish	INX/ADM/ETC			EULAR/ΔDAS28	6 and 12 months	134	Márquez *et al.*[25]
RA	Japan	INX/ADM/ETC	28.7	89.1	EULAR[c]/ΔDAS28	24 weeks	101	Nishimoto *et al.*[31]
RA	Spain	INX/ADM/ETC	78.9		EULAR[c]	6,12,18 and 24 months	199	Dávila-Fajardo *et al.*[31]
RA	Greece	INX/ADM/ETC	—	—	EULAR[c]/ΔDAS28	6 months	183	Zervou *et al.*[55]
RA	United Kingdom	INX/ADM/ETC	—	—	EULAR[c, g]/ΔDAS28	6 months	1278	Mathews *et al.*[44]
RA	Spain	INX/ADM/ETC	—	—	EULAR[g]/ΔDAS28[d]	12 weeks	315	Acosta-Colman *et al.*[59]
RA	Italy	ADM	—	—	EULAR	12 weeks	377	Ceccarelli *et al.*[30]
RA	United Kingdom	INX/ADM/ETC	73	—	EULAR[g]/ΔDAS28[d]	6 months	1115	Plant *et al.*[47]
RA	The Netherland	INX/ADM	—	61.0	EULAR[i]	3 months	182	Coenen *et al.*[38]
RA	Sweden	ADM/ETC	—	68.8	EULAR[i]	3 months	269	Coenen *et al.*[38]
RA	United Kingdom	INX/ADM/ETC	68	—	ΔDAS28 and EULAR[c]	6 months	1102	Coulthard *et al.*[39]
RA	United Kingdom	INX/ADM/ETC	72	—	ΔDAS28 and EULAR[c]	6 months	909	Potter *et al.*[48]
RA	United Kingdom	INX/ADM/ETC	72.7	—	ΔDAS28 and EULAR[f]	6 months	1334	Tan *et al.*[53]
RA	Spain	INX/ADM/ETC	—	—	EULAR[f]/ΔDAS28[j]	3 months	151	Suarez-Gestal *et al.*[51]
RA	Multi-cohorts[k]	INX/ADM/ETC	—	0–100	EULAR[g]/ΔDAS28	3–12 months	1283	Cui *et al.*[40]
RA	United Kingdom	INX/ADM/ETC	—	—	ΔDAS28	6 months	602	Potter *et al.*[36]
RA	Caucasian	INX/ADM/ETC	—	—	EULAR[i]/ΔDAS28	6 months	1050	Hassan *et al.*[41]
RA	United Kingdom	INX/ADM/ETC	73	—	ΔDAS28	6 months	624	Bowes *et al.*[26]
RA	United Kingdom	INX/ADM/ETC	68	—	ΔDAS28	6 months	411	Bowes *et al.*[26]
RA	United Kingdom	INX/ADM/ETC	69	—	EULAR[g]/ΔDAS28	6 months	1050	Maxwell *et al.*[57]
RA	The Netherland	INX/ADM	—	—	ΔDAS28	3 and 6 months	234	Toonen *et al.*[54]
RA	United Kingdom	INX/ADM/ETC	73	—	ΔDAS28	6 months	642	Potter *et al.*[49]
RA	Italy	INX/ADM/ETC	—	—	ΔDAS28/ACR20/50/70[l]	12 months	105	Ongaro *et al.*[45]
RA	Spain	INX	—	—	ΔDAS28[d]	30 weeks	113	Pinto *et al.*[35]
RA	France	ADM	72	47	ACR50[m]	12 weeks	388	Miceli-Richard *et al.*[27]
JIA	Caucasian	INX/ADM/ETC			ACR Pedi 30	3 months	107	Cimaz *et al.*[37]
RA	Sweden	INX/ ETC	—	—	EULAR/ACR20/50/70[l]	3 months	282	Kastbom *et al.*[42]
JIA	Caucasian	ETC	—	—	ACR-JRA 30[n]	3 months	137	Schmeling *et al.*[50]
RA	France	INX	—	—	ARC20[o]	30 weeks	198	Marotte *et al.*[43]
RA	Sweden	ETC	—	—	ARC20[o]/ΔDAS28	3 months	123	Padyukov *et al.*[46]
GWAS								
RA	Japanese	INX/ADM/ETC	—	—	ΔDAS28	3 and 6 months	444	Honne *et al.*[60]
RA	Spanish	INX/ADM/ETC	—	—	EULAR	12 weeks	361	Julià *et al.*[61]
RA	Dutch	INX/ADM/ETC	—	—	ΔDAS28	3 months	984	Umicevic et.al.[64]

Table 1. (Continued)

Disease	*Ethnicity/country*	*Biological drug(s)*	*DMARDs*[a] *(%)*	*MTX*[a] *(%)*	*Response criteria bases on*	*Response evaluated after*	N *cases*	*Refs.*
RA	Danish	INX/ADM/ETC	—	—	EULAR/ΔDAS28	14 weeks	196	Krintel *et al.*[62]
RA	Great Britain	INX/ADM/ETC	—	—	ΔDAS28[p]	6 months	566	Plant *et al.*[63]

Abbreviations: ACR, American College of Rheumatology outcome measure % improvement; ADM, adalimumab; DAS28, disease activity score for 28 joints; DMARDs, disease-modifying antirheumatic drugs; ETC, etanercept; EULAR, European League Against Rheumatism; INX, infliximab; JIA, juvenile idiopathic arthritis; MTX, methotrexate; RA, rheumatoid arthritis. [a]Treatment with additional drugs during biological treatment. [b]EULAR response was classified into. Good responders are those with $\Delta DAS28 \geqslant 1, 2$ and $DAS28 \leqslant 3$, 2. Non-responders are all the patients with $\Delta DAS28 < 0, 6$ and those with $\Delta DAS28 > 0, 6$ but $\leqslant 1, 2$ and $DAS28 > 5$, 1. All the remaining patients are moderate responders. [c]EULAR response were defined as good and moderate response. [d]Good responders are those with $\Delta DAS28 \geqslant 1, 2$ and $DAS28 \leqslant 3$, 2. Non-responders are all the patients with $\Delta DAS28 < 0, 6$ and those with $\Delta DAS28 > 0, 6$ but $\leqslant 1, 2$ and $DAS28 > 5$, 1. All the remaining patients are moderate responders. [e]Spain, Portugal and Romania. [f]EULAR defines anti-TNF response in three categories: good, moderate and non-response—moderate response were removed and good versus non-response were analysed. [g]EULAR response were defined as good response. [h]EULAR response were defined as remission and low disease activity. [i]EULAR response were not specific defined as seen in refs 6 and 7. [j]Anti-TNF response was evaluated by absolute ($\Delta DAS28$) and relative ($\Delta DAS28/DAS28_{baseline}$) DAS28 score change. [k]ABCoN ($n = 116$), AMC ($n = 157$), BeSt ($n = 126$), BRAGGSS ($n = 81$) BRASS ($n = 55$) EIRA ($n = 291$), ERA ($n = 218$), KI ($n = 163$), JBI ($n = 76$). [l]ARC20, 50 and 70 responses is defined if the patients have 20, 50 or 70% improvement in tender and swollen joints, respectively. Patients with ACR20, 50 or 70 response were considered low-, medium and high responders, respectively. [m]ARC50 is defined as responder if 20% improvement in tender and swollen joints were achieved as well as a 50% improvement in at least three of the five criteria: Patients assessment, physician assessment, pain scale, disability/functional questionnaire and acute phase reactant (erythrocyte sedimentation rate or C-reactive protein (CRP)). [n]ARC-JRA 30 is defined as responder if 30% improvement in tender and swollen joints were achieved as well as a 30% improvement in at least three of the five criteria: Patients assessment, physician assessment, pain scale, disability/functional questionnaire and acute phase reactant (erythrocyte sedimentation rate or CRP). [o]ARC20 is defined as responder if 20% improvement in tender and swollen joints were achieved as well as a 20% improvement in at least three of the five criteria: Patients assessment, physician assessment, pain scale, disability/functional questionnaire and acute phase reactant (erythrocyte sedimentation rate or CRP). [p]Anti-TNF response was evaluated by absolute ($\Delta DAS28$) and relative ($\Delta DAS28/DAS28_{baseline}$) DAS28 score change.

Statistical analyses were performed in Stata version 14 (StataCorp, Collage Station, TX, USA) using the meta-analysis plugin, metan. Random effects models were specified as the studies included were based on samples from heterogeneous populations. Heterogeneity is reported as I^2.[20]

We also evaluated the potential for predicting treatment response based on genotyping using a data set (15–17) with information on a cohort of RA patients treated with anti-TNF. We first estimated associations between single nucleotide polymorphisms (SNPs) and non-response using logistic (EULAR) and linear regression ($\Delta DAS28$) to identify significant associations and to determine dominance of alleles. After dichotomising SNPs based on allelic dominance, five genotypes were significantly associated with non-response. We finally tested the association between the number of risk genotypes and treatment non-response using logistic regression, and positive and negative predictive values of each level.

RESULTS

In total, 47 studies were included in the analysis; 42 candidate gene studies[14–16,21,22–59] and 5 genome-wide association studies (GWAS)[60–64] analysing responders versus non-responders from anti-TNF therapy in RA (Table 1). Two studies reported associations between polymorphisms and treatment response in juvenile idiopathic arthritis (JIA)[37,50] and the others on adult RA. The studies differed according to the studied population, response criteria and elapsed time before evaluation of response (Table 1).

Table 2 shows polymorphisms associated with response to anti-TNF treatment in RA identified by GWS. Response criteria as well as study design differed among the studies as described in Table 2. In total 19 polymorphisms, including polymorphisms in

Table 2. Identified genetic markers associated with response after anti-TNF treatment of RA patients in GWS

SNPs	*Statistical criteria*	*Refs.*
rs284515 rs75908454 rs1679568	$P < 10^{-6}$	Honne *et al.*[60]
rs113878252[a] rs4411591 rs7767069 rs4651370 rs1813443	$P < 10^{-7}$, for replication $P < 0.05$	Julià *et al.*[61]
rs1447722 rs1568885 rs12142623 rs2378945	$P < 10^{-3}$, $P < 0.05$ in two replication steps	Umicevic *et al.*[64]
None rs12081765 rs1532269 rs17301249	$P < 5 \times 10^{-8}$	Krintel *et al.*[62]
rs7305646 rs4694890 rs1350948 rs7962316	$P < 10^{-3}$, the statistical signal remained the same or diminished in significance in the second meta-analyses	Plant *et al.*[63]

[a]rs113878252 was statistically significant in a subgroup of etanercept-treated patients in discovery cohort of 372 participants genotyped with Illumina Quad610 ($P < 1e–7$). Replication genotyping was performed in 245 patients (115 etanercept-treated) using Illumina GoldenGate (San Diego, CA) using the closest most significant non-imputed SNP for replication (rs4821915).



Figure 2. Meta-analyses of 6 polymorphisms in 6 genes, which were associated with treatment response in rheumatoid arthritis (RA).

Table 3. Positive and negative prediction values for selected genotypes in an exploratory analyses based on data from Sode *et al.*[14–16]

No. of risk genotypoes	*Response* (n)	*Non-response* (n)	*Logistic regression predicting non-response*			*Predictive values*	
			Crude OR	*Adj.OR*	*Adj. 95% CI*	*Pos.*	*Neg.*
0	18	3	(Ref. odds = 0.17)	—	—	0.86	0.14
1	70	30	2.57	3.08	(0.83, 11.49)	0.7	0.3
2	113	55	2.92	3.36	(0.93, 12.13)	0.67	0.33
3	59	52	5.29*	6.03**	(1.65, 22.06)	0.53	0.47
4	9	9	6.00*	6.35*	(1.32, 30.48)	0.5	0.5

$N = 418$. Non-response versus full or partial response. Adjusted for: gender, DAS28, HAQ and DMARD status at baseline. Risk genotypes: CHUK rs11591741 (CC), IKBKB rs11986055 (CC), IFNGR2 rs17882748 (CT/TT), IL6 rs10499563 (CT/TT), NLRP3 rs4612666 (CT/TT). *$P < 0.05$, **$P < 0.01$. Data from Sode *et al.*[14–16]

WDR27, GFRA1, MED15, LINC01387, LOC102723883, CNTN5, NUBPL, PDZD2, EYA4, TEC and *C12orf79* were identified.

The polymorphisms investigated in candidate gene studies in relation to the outcome from anti-TNF treatment of patients with RA and JIA are shown in Supplementary Table 2. Hundreds of polymorphisms in various pathways have been selected for evaluation as candidate genes. Many of the assessed polymorphisms were found to be associated with response after anti-TNF treatment in one study. However, only few of these polymorphisms have been sought replicated in other candidate gene studies.

Supplementary Table 3 shows the ORs and 95% CI for the associations between polymorphism and treatment response for

Table 4. Proposed functions of selected polymorphisms that are identified in GWS or meta-analysis as associated with treatment response in RA

SNPs	*Gene*	*MAF*	*Allele*	*Proposed function of genes/proteins and SNPs associated with treatment response in RA*
rs3761847	*TRAF1*	0.46	G	Gene/protein function: This protein and TRAF2 form a heterodimeric complex, which is required for TNF-alpha-mediated activation of MAPK8/JNK and NF-kappaB SNP function: rs3761847 is associated with changes in mRNA levels. However, the direction of the effect differs between tissue types (GTEx, http://www.gtexportal.org.). Furthermore, rs3761847GG homozygotes have higher Gp210 autoantibody as compared with AA homozygotes. In contrast, rs3761847AA homozygotes have higher antichromatin as compared to GG homozygotes.[66] In addition, rs3761847GG homozygotes increases the risk of death in RA and appears to be independent of RA activity and severity as well as comorbidities relevant to cardiovascular disease[67]
rs4612666	*NLRP3*	0.41	T	Gene/protein function: A member of the NALP3 inflammasome complex. This complex functions as an upstream activator of NF-kappaB signalling, and it has a role in the regulation of inflammation, the immune response and apoptosis SNP function: rs4612666T decreases expression[68]
rs9403	*NFKBIB*	0.45	C	Gene/protein function: Inhibit NF-kappa-B by complexing with, and trapping it in the cytoplasm SNP function: rs9403 is associated with changes in mRNA levels. However, the direction of the effect differs between tissue types (GTEx, http://www.gtexportal.org.)
rs1061622	*TNFRSF1B*	0.19	G	Gene/protein function: The protein encoded by this gene is thought to potentiate TNF-induced apoptosis by the ubiquitination and degradation of TNF-receptor-associated factor 2, which mediates anti-apoptotic signals SNP function: Unknown
rs1801274	*FCGR2A*	0.44	G	Gene/protein function: Member of a family of immunoglobulin Fc receptor genes found on the surface of many immune response cells that is involved in the process of phagocytosis and clearing of immune complexes. Autoimmune diseases with elevated circulating autoantibodies drive tissue damage and the onset of disease. The Fcγ receptors bind IgG subtypes modulating the clearance of circulating immune complexes. SNP function: rs1801274 at nucleotide 519 is involved in its ligand binding domain, causing an arginine (G-allele) to histidine (A-allele) amino acid substitution at position 131. The FcγRIIa-H131 shows higher binding efficiency for CRP[65] and human IgG2 and IgG3 isoforms, compared to FcγRIIa-R131[69]

Abbreviation: CRP, C-reactive protein.

polymorphisms that were significantly associated with response in more than one cohort. In total, 23 polymorphisms in 21 genes were identified. These polymorphisms were selected for meta-analyses. Figure 2 shows the results for 6 polymorphisms in 6 genes (*CHUK, PTPRC, TRAF1/C5, NFKBIB, FCGR2A* and *IRAK3)* that were associated with treatment response in our meta-analyses. Supplementary Figure 1 shows the results for 17 polymorphisms in 16 genes (including *FCGR3A, TNF, CD226, MAPKAPKA, RPS6KA5, MAP2K6, TLR5, TLR1, IFNG, IKBKB* and *TLR10*) that were not associated with treatment response.

Next, to evaluate the current status of clinical use of the biomarkers we perform an explorative analysis of one cohort with available genotyping data.[14–16] First, we used logistic regression to identify genotypes associated with non-response (risk genotypes) (*CHUK* rs11591741 (CC), *IKBKB* rs11986055 (CC), *IFNGR2* rs17882748 (CT/TT), *IL6* rs10499563 (CT/TT), *NLRP3* rs4612666 (CT/TT)). Next, we calculated the OR and 95% CI based on the number of risk genotypes (Table 3; Supplementary Table 4). OR for non-response increased dose-dependently with the number of risk genotypes carried by the patients. For example, individuals with 4 out of 5 non-response-associated genotypes had an OR of 6.35 (95% CI: 1.32–30.48) and a negative predictive value of 0.5. The reference group of individuals with none of the five risk genotypes had the lowest odds (0.17) for non-response and a positive predictive value of 0.86 (indicating a somewhat higher chance of effective treatment than the first-best average (60–70%)).

DISCUSSION

We identified polymorphisms associated with treatment outcome from anti-TNF treatment in RA patients from 47 studies with available data (Table 1). Among the 25 polymorphisms that were identified, 19 polymorphisms were found in GWS (Table 2). Our meta-analyses further identified 6 polymorphisms in 6 genes (Figure 2). Furthermore, we analysed the potential predictive power in an exploratory analysis of an available cohort.[14–16] We found increasing OR for carrying increasing numbers of non-response associated polymorphisms (Table 3; Supplementary Table 4). However, the positive and negative predictive values were moderate.

Knowledge on the biological pathways involved in the treatment response in RA may allow for development of new treatment strategies. The results suggest that genetic variants in *CTCN5, NUBPL, PD2D2, EYA4* and *TEC* (from the GWS), and *CHUK, PTPRC, TRAF1/C5, NFKBIB, FCGR2A* and *IRAK3* (from our meta-analysis) may be implicated in treatment response to anti-TNF drugs in RA (Tables 2 and 4, Figure 2 and Supplementary Table 5). Some of the polymorphisms may indeed be functional or be linked to functional polymorphisms. Rs3761847 in *TRAF1/C5* is associated with changes in mRNA levels. However, the direction of the effect differs between tissue types (GTEx, http://www.gtexportal.org.). Likewise, rs9403 in *NFKBIB* has been associated with allele-specific mRNA levels with the variant alleles having the highest expression in liver (GTEx, http://www.gtexportal.org.). *FCGR2A* rs1801274 is also a missense polymorphism resulting in a non-conservative amino acid substitution (His to Arg). The variant receptor has lowered affinity towards CRP.[65] The lack of associations may suggest that the assessed genes are not of major importance for treatment response provided that the studies had sufficient power and the investigated polymorphisms are functional themselves or linked to functional polymorphisms. Our meta-analyses suggested that *FCGR3A, TNF, CD226, MAPKAPKA, RPS6KA5, MAP2K6, TLR5, TLR1, IFNG, IKBKB* and *TLR10* were not associated with response after anti-TNF treatment in RA (Supplementary Figure 1).

Recently, we performed a review and meta-analysis of genes involved in response to anti-TNF treatment in patients with inflammatory bowel disease (IBD).[12] SNPs involved in the TLR signalling pathway were found to be associated with anti-TNF treatment response in IBD, thus suggesting a significant role for

the host–microbial interaction. Thus, different genes have been identified to be involved in RA and IBD treatment response to anti-TNF therapy. This may suggest that genes involved in the adaptive immune response may have a larger role in RA than in IBD treatment response to anti-TNF therapy. However, the role of host–microbial interactions in RA is not clear. Patients with active RA were found to have dysbiosis in the gut microbiota that partly resolved after medical treatment.[70] The reason for this observation and how it may relate to treatment mechanism(s) is not known.

RA is a highly heterogeneous disease in terms of clinical presentation, prognosis and response to treatment.[71] It is likely that this also applies to the pathogenesis of RA, in fact, studies have shown pronounced heterogeneity in RA synovial tissue of inflammatory cell types and gene expression.[72] Through an improved discrimination of different RA subsets, SNP associations may prove to be more clinically useful, as they could at least in theory be very important for a certain subgroup while irrelevant for others.

An explorative approach was used when identifying potential candidate biomarkers in order not to overlook relevant candidates. Response criteria varied between the reviewed studies and more than one criterion were used in most studies. Our findings may furthermore be subject to bias from, for example, publication bias and selective reporting within studies. Replication of findings in other cohorts is of major importance in studies of genetic epidemiology. Therefore, replication of the findings in another cohort was chosen as criterion for association in the present review. Furthermore, environmental factors such as nutrition, smoking, lifestyle and other medication may impact genetic susceptibility and treatment outcome. These factors may not have been captured in the present studies.

Further evaluation of pharmacogenetics of anti-TNF treatment response in rheumatoid arthritis including gene–environmental interactions will require large cohorts of well-characterised patients and replication of positive findings in other cohorts. This work necessitates collaboration between researchers, for example, via International Consortia. Investigations of genomics combined with microbiome and mucosa expression profiles in each patient may thus allow us to understand which pathways and cytokines are deregulated in each case. Such knowledge may be utilised to select the best treatment for each patient.

However, at present, the pharmacogenomic basis for stratifying patients according to the expected response to anti-TNF treatment is not yet available.

CONFLICT OF INTEREST

VA receives compensation as a consultant and an advisory board member for Merck (MSD) and Janssen. The remaining authors declare no conflict of interest.

ACKNOWLEDGMENTS

We would like to thank Staff at the Libraries, Regional Hospital Viborg and Hospital of Southern Jutland for their help. VA was supported by 'Knud og Edith Eriksens Mindefon'.

REFERENCES

1 Symmons D, Turner G, Webb R, Asten P, Barrett E, Lunt M *et al*. The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. *Rheumatology* 2002; **41**: 793–800.
2 Feldmann M, Maini SR. Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics. *Immunol Rev* 2008; **223**: 7–19.
3 Bottazzo GF, Pujol-Borrell R, Hanafusa T, Feldmann M. Role of aberrant HLA-DR expression and antigen presentation in induction of endocrine autoimmunity. *Lancet* 1983; **2**: 1115–1119.
4 Londei M, Lamb JR, Bottazzo GF, Feldmann M. Epithelial cells expressing aberrant MHC class II determinants can present antigen to cloned human T cells. *Nature* 1984; **312**: 639–641.
5 Pujol-Borrell R, Todd I, Doshi M, Bottazzo GF, Sutton R, Gray D *et al*. HLA class II induction in human islet cells by interferon-gamma plus tumour necrosis factor or lymphotoxin. *Nature* 1987; **326**: 304–306.
6 Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IT *et al*. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. *Arthritis Rheum* 2010; **62**: 22–32.
7 Smolen JS, Weinblatt ME, van der Heijde D. Efficacy and safety of tabalumab, an anti-B-cell-activating factor monoclonal antibody, in patients with rheumatoid arthritis who had an inadequate response to methotrexate therapy: results from a phase III multicentre, randomised, double-blind study. *Ann Rheum Dis* 2015; **74**: 1567–1570.
8 Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P. New therapies for treatment of rheumatoid arthritis. *Lancet* 2007; **370**: 1861–1874.
9 Tarnowski M, Paradowska-Gorycka A, Dabrowska-Zamojcin E, Czerewaty M, Sluczanowska-Glabowska S, Pawlik A. The effect of gene polymorphisms on patient responses to rheumatoid arthritis therapy. *Expert Opin Drug Metab Toxicol* 2016; **12**: 41–55.
10 Plant D, Wilson AG, Barton A. Genetic and epigenetic predictors of responsiveness to treatment in RA. *Nat Rev Rheumatol* 2014; **10**: 329–337.
11 Bank S, Andersen PS, Burisch J, Pedersen N, Roug S, Galsgaard J *et al*. Polymorphisms in the toll-like receptor and the IL-23/IL-17 pathways were associated with susceptibility to inflammatory bowel disease in a Danish cohort. *PLoS ONE* 2015; **10**: e0145302.
12 Bek S, Nielsen JV, Bojesen AB, Franke A, Bank S, Vogel U *et al*. Systematic review: genetic biomarkers associated with anti-TNF treatment response in inflammatory bowel diseases. *Alimen Pharmacol Therap* 2016; **44**: 554–567.
13 Bank S, Andersen PS, Burisch J, Pedersen N, Roug S, Galsgaard J *et al*. Associations between functional polymorphisms in the NFkappaB signaling pathway and response to anti-TNF treatment in Danish patients with inflammatory bowel disease. *Pharmacogenomics J* 2014; **14**: 526–534.
14 Sode J, Vogel U, Bank S, Andersen PS, Hetland ML, Locht H *et al*. Genetic variation in the TLR5 locus is associated with anti-TNF response among rheumatoid arthritis patients. *Arthritis Rheumatol* 2014; **66**: S1092–S1093.
15 Sode J, Vogel U, Bank S, Andersen PS, Hetland ML, Locht H *et al*. Confirmation of an IRAK3 polymorphism as a genetic marker predicting response to anti-TNF treatment in rheumatoid arthritis. *Pharmacogenomics J* 2016; doi: 10.1038/tpj.2016.66 [Epub ahead of print].
16 Sode J, Vogel U, Bank S, Andersen PS, Hetland ML, Locht H *et al*. Genetic variations in pattern recognition receptor loci are associated with anti-TNF response in patients with rheumatoid arthritis. *PLoS ONE* 2015; **10**: e0139781.
17 Weng L, Zhang L, Peng Y, Huang RS. Pharmacogenetics and pharmacogenomics: a bridge to individualized cancer therapy. *Pharmacogenomics* 2013; **14**: 315–324.
18 Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med* 2009; **6**: e1000097.
19 Fransen J, van Riel PL. The disease activity score and the EULAR response criteria. *Clin Exp Rheumatol* 2005; **23**: S93–S99.
20 Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med* 2002; **21**: 1539–1558.
21 Iwaszko M, Swierkot J, Kolossa K, Jeka S, Wiland P, Bogunia-Kubik K. Polymorphisms within the human leucocyte antigen-E gene and their associations with susceptibility to rheumatoid arthritis as well as clinical outcome of anti-tumour necrosis factor therapy. *Clin Exp Immunol* 2015; **182**: 270–277.
22 Canet LM, Filipescu I, Caliz R, Lupianez CB, Canhao H, Escudero A *et al*. Genetic variants within the TNFRSF1B gene and susceptibility to rheumatoid arthritis and response to anti-TNF drugs: a multicenter study. *Pharmacogenet Genomics* 2015; **25**: 323–333.
23 Smith SL, Plant D, Lee XH, Massey J, Hyrich K, Morgan AW *et al*. Previously reported PDE3A-SLCO1C1 genetic variant does not correlate with anti-TNF response in a large UK rheumatoid arthritis cohort. *Pharmacogenomics* 2016; **17**: 715–720.
24 Iwaszko M, Swierkot J, Kolossa K, Jeka S, Wiland P, Bogunia-Kubik K. Influence of CD94 and NKG2A variants on susceptibility to rheumatoid arthritis and efficacy of anti-TNF treatment. *Joint Bone Spine Revue du Rhumatisme* 2016; **83**: 75–79.
25 Marquez A, Ferreiro-Iglesias A, Davila-Fajardo CL, Montes A, Pascual-Salcedo D, Perez-Pampin E *et al*. Lack of validation of genetic variants associated with anti-tumor necrosis factor therapy response in rheumatoid arthritis: a genome-wide association study replication and meta-analysis. *Arthritis Res Therapy* 2014; **16**: R66.
26 Bowes JD, Potter C, Gibbons LJ, Hyrich K, Plant D, Morgan AW *et al*. Investigation of genetic variants within candidate genes of the TNFRSF1B signalling pathway on the response to anti-TNF agents in a UK cohort of rheumatoid arthritis patients. *Pharmacogenet Genomics* 2009; **19**: 319–323.
27 Miceli-Richard C, Comets E, Verstuyft C, Tamouza R, Loiseau P, Ravaud P *et al*. A single tumour necrosis factor haplotype influences the response to adalimumab in rheumatoid arthritis. *Ann Rheum Dis* 2008; **67**: 478–484.

28 Ferreiro-Iglesias A, Montes A, Perez-Pampin E, Canete JD, Raya E, Magro-Checa C *et al.* Replication of PTPRC as genetic biomarker of response to TNF inhibitors in patients with rheumatoid arthritis. *Pharmacogenomics J* 2015; **16**: 137–140.
29 Canet LM, Caliz R, Lupianez CB, Canhao H, Martinez M, Escudero A *et al.* Genetic variants within immune-modulating genes influence the risk of developing rheumatoid arthritis and anti-TNF drug response: a two-stage case–control study. *Pharmacogenet Genomics* 2015; **25**: 432–443.
30 Ceccarelli F, D'Alfonso S, Perricone C, Carlomagno Y, Alessandri C, Croia C *et al.* The role of eight polymorphisms in three candidate genes in determining the susceptibility, phenotype, and response to anti-TNF therapy in patients with rheumatoid arthritis. *Clin Exp Rheumatol* 2012; **30**: 939–942.
31 Davila-Fajardo CL, Marquez A, Pascual-Salcedo D, Moreno Ramos MJ, Garcia-Portales R, Magro C *et al.* Confirmation of -174G/C interleukin-6 gene promoter polymorphism as a genetic marker predicting antitumor necrosis factor treatment outcome. *Pharmacogenet Genomics* 2014; **24**: 1–5.
32 Davila-Fajardo CL, van der Straaten T, Baak-Pablo R, Medarde Caballero C, Cabeza Barrera J, Huizinga TW *et al.* FcGR genetic polymorphisms and the response to adalimumab in patients with rheumatoid arthritis. *Pharmacogenomics* 2015; **16**: 373–381.
33 Montes A, Perez-Pampin E, Joven B, Carreira P, Fernandez-Nebro A, Del Carmen Ordonez M *et al.* FCGR polymorphisms in the treatment of rheumatoid arthritis with Fc-containing TNF inhibitors. *Pharmacogenomics* 2015; **16**: 333–345.
34 Nishimoto T, Seta N, Anan R, Yamamoto T, Kaneko Y, Takeuchi T *et al.* A single nucleotide polymorphism of TRAF1 predicts the clinical response to anti-TNF treatment in Japanese patients with rheumatoid arthritis. *Clin Exp Rheumatol* 2014; **32**: 211–217.
35 Pinto JA, Rego I, Rodriguez-Gomez M, Canete JD, Fernandez-Lopez C, Freire M *et al.* Polymorphisms in genes encoding tumor necrosis factor-alpha and HLA-DRB1 are not associated with response to infliximab in patients with rheumatoid arthritis. *J Rheumatol* 2008; **35**: 177–178.
36 Potter C, Gibbons LJ, Bowes JD, Cordell HJ, Hyrich K, Isaacs JD *et al.* Polymorphisms spanning the TNFR2 and TACE genes do not contribute towards variable anti-TNF treatment response. *Pharmacogenet Genomics* 2010; **20**: 338–341.
37 Cimaz R, Cazalis MA, Reynaud C, Gerloni V, Zulian F, Biggioggero M *et al.* IL1 and TNF gene polymorphisms in patients with juvenile idiopathic arthritis treated with TNF inhibitors. *Ann Rheum Dis* 2007; **66**: 900–904.
38 Coenen MJ, Enevold C, Barrera P, Schijvenaars MM, Toonen EJ, Scheffer H *et al.* Genetic variants in toll-like receptors are not associated with rheumatoid arthritis susceptibility or anti-tumour necrosis factor treatment outcome. *PLoS ONE* 2010; **5**: e14326.
39 Coulthard LR, Taylor JC, Eyre S, Biologics in Rheumatoid Arthritis Genetics and Genomics, Robinson JI, Wilson AG. Genetic variants within the MAP kinase signalling network and anti-TNF treatment response in rheumatoid arthritis patients. *Ann Rheum Diseases* 2011; **70**: 98–103.
40 Cui J, Saevarsdottir S, Thomson B, Padyukov L, van der Helm-van Mil AH, Nititham J *et al.* Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy. *Arthritis Rheum* 2010; **62**: 1849–1861.
41 Hassan B, Maxwell JR, Hyrich KL, Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate, Barton A, Worthington J. Genotype at the sIL-6R A358C polymorphism does not influence response to anti-TNF therapy in patients with rheumatoid arthritis. *Rheumatology* 2010; **49**: 43–47.
42 Kastbom A, Bratt J, Ernestam S, Lampa J, Padyukov L, Soderkvist P *et al.* Fcgamma receptor type IIIA genotype and response to tumor necrosis factor alpha-blocking agents in patients with rheumatoid arthritis. *Arthritis Rheum* 2007; **56**: 448–452.
43 Marotte H, Pallot-Prades B, Grange L, Tebib J, Gaudin P, Alexandre C *et al.* The shared epitope is a marker of severity associated with selection for, but not with response to, infliximab in a large rheumatoid arthritis population. *Ann Rheum Dis* 2006; **65**: 342–347.
44 Mathews RJ, Robinson JI, Battellino M, Wong C, Taylor JC, Biologics in Rheumatoid, Arthritis G *et al.* Evidence of NLRP3-inflammasome activation in rheumatoid arthritis (RA); genetic variants within the NLRP3-inflammasome complex in relation to susceptibility to RA and response to anti-TNF treatment. *Ann Rheum Dis* 2014; **73**: 1202–1210.
45 Ongaro A, De Mattei M, Pellati A, Caruso A, Ferretti S, Masieri FF *et al.* Can tumor necrosis factor receptor II gene 676T>G polymorphism predict the response grading to anti-TNFalpha therapy in rheumatoid arthritis? *Rheumatol Int* 2008; **28**: 901–908.
46 Padyukov L, Lampa J, Heimburger M, Ernestam S, Cederholm T, Lundkvist I *et al.* Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis. *Ann Rheum Dis* 2003; **62**: 526–529.
47 Plant D, Prajapati R, Hyrich KL, Morgan AW, Wilson AG, Isaacs JD *et al.* Replication of association of the PTPRC gene with response to anti-tumor necrosis factor therapy in a large UK cohort. *Arthritis Rheum* 2012; **64**: 665–670.
48 Potter C, Cordell HJ, Barton A, Daly AK, Hyrich KL, Mann DA *et al.* Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NF{kappa}B signalling pathways. *Ann Rheum Dis* 2010; **69**: 1315–1320.
49 Potter C, Hyrich KL, Tracey A, Lunt M, Plant D, Symmons DP *et al.* Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis. *Ann Rheumatic Dis* 2009; **68**: 69–74.
50 Schmeling H, Horneff G. Tumour necrosis factor alpha promoter polymorphisms and etanercept therapy in juvenile idiopathic arthritis. *Rheumatol Int* 2007; **27**: 383–386.
51 Suarez-Gestal M, Perez-Pampin E, Calaza M, Gomez-Reino JJ, Gonzalez A. Lack of replication of genetic predictors for the rheumatoid arthritis response to anti-TNF treatments: a prospective case-only study. *Arthritis Res Therapy* 2010; **12**: R72.
52 Swierkot J, Bogunia-Kubik K, Nowak B, Bialowas K, Korman L, Gebura K *et al.* Analysis of associations between polymorphisms within genes coding for tumour necrosis factor (TNF)-alpha and TNF receptors and responsiveness to TNF-alpha blockers in patients with rheumatoid arthritis. *Joint Bone Spine Revue du Rhumatisme* 2015; **82**: 94–99.
53 Tan RJ, Gibbons LJ, Potter C, Hyrich KL, Morgan AW, Wilson AG *et al.* Investigation of rheumatoid arthritis susceptibility genes identifies association of AFF3 and CD226 variants with response to anti-tumour necrosis factor treatment. *Ann Rheum Dis* 2010; **69**: 1029–1035.
54 Toonen EJ, Coenen MJ, Kievit W, Fransen J, Eijsbouts AM, Scheffer H *et al.* The tumour necrosis factor receptor superfamily member 1b 676T>G polymorphism in relation to response to infliximab and adalimumab treatment and disease severity in rheumatoid arthritis. *Ann Rheum Dis* 2008; **67**: 1174–1177.
55 Zervou MI, Myrthianou E, Flouri I, Plant D, Chlouverakis G, Castro-Giner F *et al.* Lack of association of variants previously associated with anti-TNF medication response in rheumatoid arthritis patients: results from a homogeneous Greek population. *PLoS ONE* 2013; **8**: e74375.
56 Montes A, Perez-Pampin E, Narvaez J, Canete JD, Navarro-Sarabia F, Moreira V *et al.* Association of FCGR2A with the response to infliximab treatment of patients with rheumatoid arthritis. *Pharmacogenet Genomics* 2014; **24**: 238–245.
57 Maxwell JR, Potter C, Hyrich KL, Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate, Barton A *et al.* Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis. *Hum Mol Genet* 2008; **17**: 3532–3538.
58 Canhao H, Rodrigues AM, Santos MJ, Carmona-Fernandes D, Bettencourt BF, Cui J *et al.* TRAF1/C5 but not PTPRC variants are potential predictors of rheumatoid arthritis response to anti-tumor necrosis factor therapy. *BioMed Res Int* 2015; **2015**: 490295.
59 Acosta-Colman I, Palau N, Tornero J, Fernandez-Nebro A, Blanco F, Gonzalez-Alvaro I *et al.* GWAS replication study confirms the association of PDE3A-SLCO1C1 with anti-TNF therapy response in rheumatoid arthritis. *Pharmacogenomics* 2013; **14**: 727–734.
60 Honne K, Hallgrimsdottir I, Wu C, Sebro R, Jewell NP, Sakurai T *et al.* A longitudinal genome-wide association study of anti-tumor necrosis factor response among Japanese patients with rheumatoid arthritis. *Arthritis Res Therapy* 2016; **18**: 12.
61 Julia A, Fernandez-Nebro A, Blanco F, Ortiz A, Canete JD, Maymo J *et al.* A genome-wide association study identifies a new locus associated with the response to anti-TNF therapy in rheumatoid arthritis. *Pharmacogenomics J* 2015; **16**: 147–150.
62 Krintel SB, Palermo G, Johansen JS, Germer S, Essioux L, Benayed R *et al.* Investigation of single nucleotide polymorphisms and biological pathways associated with response to TNFalpha inhibitors in patients with rheumatoid arthritis. *Pharmacogenet Genomics* 2012; **22**: 577–589.
63 Plant D, Bowes J, Potter C, Hyrich KL, Morgan AW, Wilson AG *et al.* Genome-wide association study of genetic predictors of anti-tumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci. *Arthritis Rheum* 2011; **63**: 645–653.
64 Umicevic Mirkov M, Cui J, Vermeulen SH, Stahl EA, Toonen EJ, Makkinje RR *et al.* Genome-wide association analysis of anti-TNF drug response in patients with rheumatoid arthritis. *Ann Rheum Dis* 2013; **72**: 1375–1381.
65 Stein MP, Edberg JC, Kimberly RP, Mangan EK, Bharadwaj D, Mold C *et al.* C-reactive protein binding to FcgammaRIIa on human monocytes and neutrophils is allele-specific. *J Clin Invest* 2000; **105**: 369–376.
66 Kempinska-Podhorodecka A, Shums Z, Wasilewicz M, Wunsch E, Milkiewicz M, Bogdanos DP *et al.* TRAF1 gene polymorphism correlates with the titre of Gp210 antibody in patients with primary biliary cirrhosis. *Clin Dev Immunol* 2012; **2012**: 487521.
67 Panoulas VF, Smith JP, Nightingale P, Kitas GD. Association of the TRAF1/C5 locus with increased mortality, particularly from malignancy or sepsis, in patients with rheumatoid arthritis. *Arthritis Rheum* 2009; **60**: 39–46.

68 Hitomi Y, Ebisawa M, Tomikawa M, Imai T, Komata T, Hirota T *et al*. Associations of functional NLRP3 polymorphisms with susceptibility to food-induced anaphylaxis and aspirin-induced asthma. *J Allergy Clin Immunol* 2009; **124**: 779–785e776.
69 Lopez-Escamez JA, Saenz-Lopez P, Gazquez I, Moreno A, Gonzalez-Oller C, Soto-Varela A *et al*. Polymorphisms of CD16A and CD32 Fcgamma receptors and circulating immune complexes in Meniere's disease: a case-control study. *BMC Med Genet* 2011; **12**: 2.
70 Zhang X, Zhang D, Jia H, Feng Q, Wang D, Liang D *et al*. The oral and gut microbiomes are perturbed in rheumatoid arthritis and partly normalized after treatment. *Nat Med* 2015; **21**: 895–905.
71 van der Pouw Kraan TC, van Gaalen FA, Kasperkovitz PV, Verbeet NL, Smeets TJ, Kraan MC *et al*. Rheumatoid arthritis is a heterogeneous disease: evidence for differences in the activation of the STAT-1 pathway between rheumatoid tissues. *Arthritis Rheum* 2003; **48**: 2132–2145.
72 Dennis G Jr., Holweg CT, Kummerfeld SK, Choy DF, Setiadi AF, Hackney JA *et al*. Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics. *Arthritis Res therapy* 2014; **16**: R90.

Supplementary Information accompanies the paper on the *The Pharmacogenomics Journal* website (http://www.nature.com/tpj)